To compare lipid and vasomotor effects, endometrial safety, and clinical acceptability of a sequential continuous HRT regimen employing conjugated estrogen (0.625 mg, days 1‐ 28/cycle) and medrogestone (5 mg. days 17‐28 cycle) versus tibolone (2.5 mg daily), we carried out an open, randomized, parallel group, multinational out‐patient study. Healthy postmenopausal women (n= 156), aged 45‐65 years, were enrolled and randomly allocated to one of the two treatment groups. Treatment continued for a total of 13 cycles.
Sequential Conjugated Estrogens Plus Medrogestone HRT Regimen Versus Tibolone: A Comparative Randomized Study
OMODEI, Umberto;
1995-01-01
Abstract
To compare lipid and vasomotor effects, endometrial safety, and clinical acceptability of a sequential continuous HRT regimen employing conjugated estrogen (0.625 mg, days 1‐ 28/cycle) and medrogestone (5 mg. days 17‐28 cycle) versus tibolone (2.5 mg daily), we carried out an open, randomized, parallel group, multinational out‐patient study. Healthy postmenopausal women (n= 156), aged 45‐65 years, were enrolled and randomly allocated to one of the two treatment groups. Treatment continued for a total of 13 cycles.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
